文献速递白血病造血干细胞移植与细胞治疗

奥英妥珠单抗治疗儿童及青少年复发或难治性B细胞急性淋巴细胞白血病的II期试验:儿童肿瘤学组AALL1621方案

Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
PubMed 文献 · J Clin Oncol · 2022-01-10

儿童肿瘤学组AALL1621单臂II期试验纳入48例1-21岁复发或难治性CD22阳性B细胞急性淋巴细胞白血病患者,第1周期奥英妥珠单抗给药方案为第1天0.8 mg/m2、第8天和第15天0.5 mg/m2静脉给药,28天为一周期。第1周期后完全缓解或伴计数不完全恢复的完全缓解率为58.3%(90%CI 46.5-69.3)。造血干细胞移植后6例(28.6%)发生3级肝窦阻塞综合征,CD22表达下调被确定为耐药机制。

要点

  • 第1周期后完全缓解/完全缓解伴计数不完全恢复率为58.3%(90%CI 46.5-69.3)
  • 28例完全缓解/完全缓解伴计数不完全恢复患者中18例(66.7%)微小残留病<0.01%
  • 奥英妥珠单抗后接受造血干细胞移植的21例中6例(28.6%)发生3级肝窦阻塞综合征

核心结论

  • 奥英妥珠单抗在经重度治疗的儿童及青少年复发或难治性CD22阳性B细胞急性淋巴细胞白血病中有效且耐受性良好。
  • 造血干细胞移植后肝窦阻塞综合征和持续性血细胞减少值得关注。
  • CD22表达调节被确定为耐药机制。
  • 奥英妥珠单抗联合化疗的扩展研究正在进行中。

研究设计与样本

  • 儿童肿瘤学组AALL1621为单臂II期试验,采用两阶段设计,持续监测剂量限制性毒性和肝窦阻塞综合征。
  • 纳入年龄1-21岁复发或难治性CD22阳性B细胞急性淋巴细胞白血病患者。
  • 第1周期奥英妥珠单抗第1天0.8 mg/m2静脉给药,第8天和第15天0.5 mg/m2静脉给药,28天为一周期,第28天评估疗效。
  • CD22表达通过中心流式细胞术回顾性评估。

主要发现

  • 48例患者可评估疗效和毒性;第1周期后19例达完全缓解,9例达完全缓解伴计数不完全恢复(完全缓解/完全缓解伴计数不完全恢复率58.3%;双侧90%CI 46.5-69.3)。
  • 28例完全缓解或完全缓解伴计数不完全恢复患者中27例检测了流式细胞术微小残留病,其中18例(66.7%)微小残留病<0.01%。
  • 28例完全缓解或完全缓解伴计数不完全恢复患者中7例(25%)在第1周期第42天后仍有延迟的计数恢复。
  • 第1周期中3例(6.3%)发生3级丙氨酸氨基转移酶升高,1例发生3级高胆红素血症。
  • 奥英妥珠单抗后接受造血干细胞移植的21例患者中,6例(28.6%)发生3级肝窦阻塞综合征。

局限性

  • CD22表达为回顾性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Children's Oncology Group trial AALL1621 was conducted to prospectively determine the safety and efficacy of inotuzumab ozogamicin (InO) in pediatric and adolescent patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). PATIENTS AND METHODS: This single-arm phase II trial enrolled patients age 1-21 years with R/R CD22-positive B-ALL. In cycle 1, InO dosing was 0.8 mg/m2 intravenously on day 1 and 0.5 mg/m2 on days 8 and 15 of a 28-day cycle with response evaluation at day 28. Using a two-stage design, the trial was continuously monitored for dose-limiting toxicities and sinusoidal obstruction syndrome (SOS). CD22 expression was retrospectively evaluated by central flow cytometry. RESULTS: Forty-eight patients were evaluable for response and toxicity; 19 had complete response (CR) and nine CR with incomplete count recovery (CRi) after cycle 1 (CR/CRi rate: 58.3%; two-sided 90% CI, 46.5 to 69.3). Twenty-seven of 28 patients with CR or CRi had minimal residual disease measured by flow cytometry; 18 (66.7%) had minimal residual disease < 0.01%. Seven of 28 patients (25%) with CR or CRi had delayed count recovery past day 42 in cycle 1. Three (6.3%) patients had grade 3 ALT elevation and one patient had grade 3 hyperbilirubinemia in cycle 1. Of 21 patients undergoing hematopoietic stem-cell transplantation after InO, 6 (28.6%) developed grade 3 SOS. Partial CD22 expression and lower CD22 site density were associated with lower likelihood of response to InO. CONCLUSION: InO is effective and well tolerated in heavily pretreated children and adolescents with R/R CD22-positive B-ALL. SOS after hematopoietic stem-cell transplantation and prolonged cytopenias were notable. CD22 modulation was identified as a mechanism of resistance. Expanded study of InO combined with chemotherapy is underway.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. O'Brien MM, Ji L, Shah NN, et al. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022. PMID: 35007127. doi:10.1200/JCO.21.01693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。